Journal of Medicinal Chemistry p. 6330 - 6345 (2019)
Update date:2022-08-15
Topics:
Amato, George
Manke, Amruta
Wiethe, Robert
Vasukuttan, Vineetha
Snyder, Rodney
Yueh, Yun Lan
Decker, Ann
Runyon, Scott
Maitra, Rangan
Peripherally restricted CB1 receptor antagonists may be useful in treating metabolic syndrome, diabetes, liver diseases, and gastrointestinal disorders. Clinical development of the centrally acting CB1 inverse agonist otenabant (1) was halted due to its p
View MoreContact:+86-913-2223392
Address:No. 32, Xinanjing Road, Weinan City, Shaanxi Province, 714000, China
Zhejiang Hoshine Silicon Industry Co., Ltd.
Contact:86-573-89179966
Address:Zhapu Town, Pinghu City, Zhejiang, China
Huaian Double Win Chemicals Co.,Ltd.
Contact:+86-13511538872
Address:Blk 43,Greenland Century Town,Huaian District, Huaian City,Jiangsu Province,China
website:http://www.tbbmed.com
Contact:86--21-50498136
Address:Room 6002, Building 7-1, No.160 Basheng Road,Pudong Area,Shanghai China
Zhejiang Chemicals Import & Export Corporation (ZHECHEM)
Contact:+86-571-87046953
Address:No. 37, Qingchun Road
Doi:10.1039/c2cc30240c
(2012)Doi:10.1246/bcsj.67.2176
(1994)Doi:10.1016/0040-4039(91)80462-F
(1991)Doi:10.1039/c2ob25073j
(2012)Doi:10.1021/jm300623u
(2012)Doi:10.1002/chem.201104073
(2012)